Modality
ASO
MOA
GLP-1ag
Target
PARP
Pathway
Complement
NASHPsA
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
Jul 2017
→ Jul 2031
Phase 3Current
NCT03760486
415 pts·NASH
2023-03→2025-07·Terminated
NCT06315848
2,725 pts·NASH
2017-07→2031-07·Terminated
3,140 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-029mo agoPh3 Readout· NASH
2031-07-265.3y awayPh3 Readout· NASH
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
P3
Termina…
Catalysts
Ph3 Readout
2025-07-02 · 9mo ago
NASH
Ph3 Readout
2031-07-26 · 5.3y away
NASH
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03760486 | Phase 3 | NASH | Terminated | 415 | EASI-75 |
| NCT06315848 | Phase 3 | NASH | Terminated | 2725 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP |